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Summary A monoclonal antibody, H317, has been used for the sensitive and specific detection of placental-
type alkaline phosphatase (PLAP) in sera, solubilized tissue extracts and fixed tumour tissue sections from
patients representing a variety of ovarian tumours. PLAP was detected in over 30% of these sera and in most
solubilized tumour tissue extracts. There was no association between circulating PLAP levels and either tissue
extract levels or immunohistological staining of ovarian tumour tissue sections with H317. Nevertheless,
immunohistology demonstrated the heterogeneity of cellular localization of PLAP within different tumours,
and can often be of value in localizing tumour tissue.
The need for improved early evaluation in ovarian
neoplasms has resulted in a number of tumour-
associated products being considered as potential
serum markers (Battacharya & Barlow, 1979; Haije,
1982). One useful marker may be placental-type
alkaline phosphatase (PLAP) (Benham et al., 1978;
Haije et al., 1979; McLaughlin et al., 1983). This
isoenzyme is a thermostable glycoprotein of human
trophoblast membranes, designated a carcino-
placental protein following its discovery in cancer
patients. Two of the main tumour-derived forms of
PLAP are the Regan enzyme, which is closely
similar to placenta-derived forms of PLAP, and the
Nagao enzyme, differing from Regan and nearly all
placenta-derived forms of PLAP by its distinct anti-
genic profile (Wei & Doellgast, 1981; McLaughlin
et al., 1984a) and sensitivity to inhibition by
L-leucine (Stigbrand et al., 1983).
PLAP can be distinguished from other human
tissue alkaline phosphatase (AP) isoenzymes by its
heat stability, amino-acid inhibition and antigenic
profile, although it is in part immunologically cross-
reactive with other AP isoenzymes (Haije et al.,
1979). However, a murine monoclonal antibody
(mAb), H317, has been shown to react Qnly with
the placental-type AP (McLaughlin et al., 1982,
1983, 1984a). This mAb reacts with various human
malignant and transformed cell lines, the reactivity
coinciding with histochemical staining for heat-
stable PLAP (McLaughlin et al., 1982). H317 has
been used in immunohistology to localize PLAP in
routinely processed and fixed tissues from primary
breast carcinomas (McDicken et al., 1983), and also
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to develop a sensitive enzyme immunoassay (EIA)
which has detected circulating PLAP in cancer
patients, particularly those with ovarian carcinoma
(McLaughlin et al., 1983). We document here the
occurrence of H317-reactive PLAP in sera, soluble
tissue extracts and fixed tissues from a variety of
ovarian cancer patients using EIA and immuno-
histology.
Materials and methods
Patients
The primary tumours or recurrences of 89 ovarian
cancer patients with established disease activity
were classified histologically (WHO) and by clinical
staging (FIGO). Of these patients, 67 had
malignant and 22 benign ovarian tumours. Controls
for the serological studies consisted of 12 patients
having abdominal hysterectomy, laparoscopy or
tubal occlusions, in whom the ovaries, after detailed
examination, appeared macroscopically normal.
Soluble tissue extracts
Samples of fresh ovarian tumour tissue from benign
and malignant disease patients were immediately
mixed with 2 vol of PBS (pH 7.4), containing
0.05% Tween 20. Homogenization was carried out
as described elsewhere (McLaughlin et al., 1984a).
After centrifugation at 3000g for 20min,
background AP activity in the supernatant was
destroyed by heating at 65°C for 1 h. Control
normal ovarian tissue was taken at postmortem
from fresh cadavers, whose previous disease or
cause of death did not involve ovarian tissue.
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Monoclonal antibody
The source of the H317 murine mAb used in this
study was spent hybridoma culture supernatants
containing 5-20 jgml-1 mouse immunoglobulin.
The H317 hybridoma had been produced after
immunization with isolated plasma membrane
preparations from syncytiotrophoblast microvilli of
normal human term placentae (Johnson et al., 1981;
Johnson & Molloy, 1983). This mAb is specific for
the heat-stable, L-phenylalanine-inhibitable, PLAP
isoenzyme and is unreactive with other AP iso-
enzymes from normal human tissues (McLaughlin
et al., 1982, 1983, 1984a). It reacts strongly with
syncytiotrophoblast in immunohistology on fixed
term placental tissue (McDicken et al., 1983).
PLAP enzyme immunoassay (EIA)
A sensitive solid-phase EIA using the H317 mAb,
described in detail previously (McLaughlin et al.,
1983, 1984a), was used to determine active PLAP in
sera collected prior to laparotomy and in fresh
tumour tissue extracts. Inhibition studies were
performed by including 5 mM L-phenylalanine,
5mM L-homoarginine or 1 mM L-leucine in the
phosphatase substrate. The lower limit of sensitivity
of this assay for PLAP in sera is 0.1 U 1- and for
PLAP in soluble tissue extracts is 0.3Ukg-1 wet
weight tissue. It has been shown previously that
none of 120 healthy individuals had circulating
PLAP levels of 0.1 U1-1 as estimated by EIA
using the H317 mAb (McLaughlin et al., 1983).
Total AP levels were estimated as described
previously (McLaughlin et al., 1983, 1984a).
Immunohistology
A peroxidase-anti-peroxidase (PAP) staining tech-
nique (McDicken et al., 1983) was used on sections
from routine formalin-fixed paraffin-embedded
tissues from the corresponding patients as for the
serological studies. Endogenous peroxidase activity
in deparaffinised sections was destroyed by first
washing in methanol containing 0.2% H202'
Controls were as previously described (McDicken
et al., 1983). Staining was considered positive when
a distinct difference could consistently be demon-
strated between test and control sections, as well
as between atypical epithelium and adjacent normal
tissues.
Results
Serological studies
The incidence of circulating PLAP detectable in
EIA using H317 was 28/89 (31%) for patients with
all types of ovarian tumour. The estimated levels of
circulating PLAP in these patients fell in the range
0.1-5.6UI1. Patients with histologically proven
malignant disease had a greater incidence of
circulating PLAP (23/67, 34%) than those with
apparently benign tumours (5/22, 23%), although
this was not statistically significant (X2 test,
P>0.05). It was of particular note that 3/7 (43%)
patients with mucinous cystadenomas had detectable
circulating PLAP, while circulating PLAP was
found in 2/6 (33%) patients with the malignant
counterpart, mucinous cystadenocarcinoma. In the
serous group, 1/9 (11%) patients with histologically
benign serous cystadenomas had detectable serum
PLAP, and 12/37 (33%) patients with serous
cystadenocarcinomas had detectable serum PLAP
(Table I). In the malignant disease group, patients
with epithelial tumours had a greater incidence of
circulating PLAP (22/62, 36%) than those with
non-epithelial tumours (1/5, 20%) (Table I). There
was no significant association between the levels of
circulating PLAP and clinical staging (Fisher's
exact test, P>0.05), although stage I disease had a
lower incidence of serum PLAP than more
advanced carcinoma (Table II). For 12 patients
with no known ovarian disease, and whose ovaries
had been checked by laparoscopy, there was no
detectable circulating PLAP (i.e. <0.1 U -1).
PLAP could be detected in trace amounts in
soluble extracts of normal and benign ovarian
Table I PLAP in sera ofpatients with ovarian tumours
Incidence
(i.e. Range of
O.1Ul-1 (U-1
PLAP) PLAP)
Malignant epithelial tumours:
Serous cystadenocarcinoma 12/37 0.1-4.0
Mucinous cystadenocarcinoma 2/6 0.8-0.9
Clear cell carcinoma 0/1
Endometrioid carcinoma 4/8 0.1-1.2
Mesonephroid carcinoma 0/2
Undifferentiated carcinoma 4/8 0.1-4.7
Malignant non-epithelial tumours:
Malignant teratoma 0/1
Granulosa cell tumour 1/3 0.6
Mixed germ cell tumour 0/1
Non-malignant epithelial tumours:
Serous cystadenoma 1/9 0.3
Mucinous cystadenoma 3/7 0.1-0.5
Endometrioma 0/2
Non-malignant non-epithelial tumours:
Cystic teratoma 0/1
Corpus luteum 0/3PLAP IN OVARIAN CANCER 61
Table II PLAP in ovarian carcinoma ofepithelial origin
Serum PLAP Stage I (%) Stage II (%) Stage III (%) Stage IV(%) Recurrence (%)
Positive
(.0.LUl'-) 1/6(17) 2/5(40) 11/31 (35) 6/14 (43) 1/6(17)
Negative
(<O.lUl-1) 5/6(83) 3/5(60) 20/31 (65) 8/14 (57) 5/6(83)
tissues by EIA using H317, whereas PLAP was
detected at increased levels in soluble extracts from
malignant ovarian tissues (Table III). However,
within the numbers of available tissues, there was
no statistically significant difference (P>0.05,
Wilcoxon rank test) between the malignant and
either the benign or normal group. Furthermore, no
quantitative correlation could be found between
tissue extract and circulating PLAP levels.
Table III PLAP in soluble ovarian tissue extracts
.w
PLAP level
(Ukg-I wet
weight tissue)
No.
Tissue source tested mean (range)
Normal ovaries 6 6.6 (<0.3-32.4)
Benign ovarian disease 8 3.4 (<0.3-10.0)
Malignant ovarian
disease 6 12.8 (1.2-53.6)
Immunohistology
A proportion of epithelial mucinous tumours, both
benign and malignant, clearly stained for PLAP
with H317. Thus, 3/7 (43%) of the benign
cystadenomas and 1/3 (33%) of the cystadeno-
carcinomas showed definite reactivity with H317.
The staining was mainly perinuclear and in the
basal part of the tumour cells, especially close to
the basement membrane, for PLAP-positive
mucinous tumours (Figure 1). Foci of unstained
tumour cells could be seen even in tissues where
most tumour cells were strongly stained by H317.
No distinctive morphological features could be
determined in PLAP-negative tumour areas to
differentiate them from the clearly PLAP-positive
tumour areas.
A proportion of epithelial serous tumours also
showed strong staining of both histologically benign
(1/5; 20%) and malignant (3/11; 27%) tumour
tissues. In the PLAP-positive benign tumours,
Figure 1 Mucinous ovarian cystadenocarcinoma
tissue stained with H317 mAb for PLAP in a PAP-
immunoperoxidase technique and showing staining of
perinuclear and basal areas of the tumour cells
(arrows). Section counterstained with haematoxylin.
x 600.
staining occurred predominantly close to the apical
membrane of these cells while, in the malignant
tumours, cytoplasmic staining was more diffusely
prominent in addition to apical staining (Figure 2).
Clear cell carcinomas showed a variable staining
pattern with 2/5 tumour tissues giving a strong
positive cell membrane reaction with H317 (Figure
3), whereas 3 were negative.
The intensity of immunohistological staining for
PLAP in ovarian tumours could not be correlated
with clinical staging. Analysis of the available data
on individual patients demonstrated that clearly
positive immunohistological staining for PLAP
showed some association with soluble tissue extract
PLAP positivity, although immunohistology was
less sensitive (Table IV).62 I.W. McDICKEN et al.
N.
Figure 2 Papillary ovarian carcinoma tissue stained
with H317 mAb for PLAP in a PAP-immuno-
peroxidase technique and showing supranuclear
cytoplasmic staining (arrow). Section counterstained
with haematoxylin. x 600.
Table IV Comparison
Figure 3 Clear cell ovarian carcinoma tissue stained
with H317 mAb for PLAP in a PAP-
immunoperoxidase technique and showing cell
membrane staining (arrow). Section counterstained
with haematoxylin. x 600.
of serum PLAP, tissue extract PLAP and immunohistology
for PLAP in ovarian tumours
Serum Tissue extract No. of cases
(0.1 Ul-1 PLAP) (.0.3 Ukg-1 PLAP) Immunohistology (n=14)
+ + + 5/14
_ + + 3/14
- + - 3/14
- - - 3/14
- - + 0/14
+ - - 0/14
+ - + 0/14
+ + - 0/14
Discussion
The H317 mAb has been used to investigate the
production and release of PLAP by ovarian
tumours using EIA and immunohistological
techniques. This mAb, which reacts with most of
the genetic phenotypes of PLAP, has been shown to
recognise tumour-derived PLAP (McLaughlin et al.,
1982, 1983; McDicken et al., 1983). In the present
study, circulating PLAP was detected in over 30%
of all patients with ovarian tumours. Circulating
PLAP has previously been reported in ovarian
cancer patients at an incidence ranging from 15%
to 65% (Fishman et al., 1975; Kellen et al., 1976;
Benham et al., 1978; Haije et al., 1979). This may
reflect differences in patient selection as well as
sensitivity and specificity of assay for PLAP. We
have detected circulating PLAP in 34% of patients
with malignant disease, while the incidence of
circulating PLAP was 23% in those with benign
tumours. Circulating PLAP levels did not appear to
correlate with stage of disease or tumour burden,
agreeing with a recent study by Doellgast &
Homesley (1984). However, in the absence of
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disease, incidence of circulating PLAP in control
sera was 0% in EIA using H317 contrasting with
31% in the study of Doellgast & Homesley (1984).
This is probably a consequence of the H317-based
assay not detecting the smoking-associated form of
PLAP found in some normal sera (McLaughlin et
al., 1984b).
Such use of mAb specific for PLAP in EIA offers
an improvement on assays based on heat stability
of PLAP or polyclonal antisera which may have
cross-reactivities for other AP isoenzymes.
However, there is some limitation associated with
the use of mAbs in that their fine specificity may
sometimes result in a lack of reactivity with
occasional forms of PLAP. H317, for example, is
known (McLaughlin et al., 1984a) not to react with
the Nagao tumour-derived form which may occur
in some ovarian carcinomas (Benham et al., 1978).
Nevertheless, single tissues can express both Regan-
like and Nagao-like PLAP forms concomitantly
(McLaughlin et al., 1984a) and most PLAP-positive
ovarian tumours co-express both Regan and Nagao
tumour-derived PLAP types (McLaughlin et al.,
unpublished). Hence, it is likely that there is no
marked underestimation of PLAP positivity in
ovarian carcinoma using H317.
PLAP could be clearly localized in ovarian
tumour tissue using the H317 mAb in an
immunoperoxidase staining technique on routinely
fixed tissues, as also recently reported using a
separate mAb (NDOG2) on frozen ovarian cancer
tissue (Sunderland et al., 1984). The distribution of
PLAP differed between serous and mucinous
tumours, with the isoenzyme being mainly
detectable towards the luminal surface of serous
epithelial cells whereas it was mainly detectable in
the perinuclear cytoplasm and towards the base of
mucinous cells. Diffuse cytoplasmic staining was
the predominant finding in the more malignant
tumours. Unstained tumour cells occurred more
frequently in the less differentiated tissues, and in
anaplastic tumours large areas were negative for
PLAP using H317. A similar juxtaposition of
staining and non-staining malignant cells within the
same tumour tissue has previously been noted
(McDicken et al., 1983). It is possible that tumour
cells express PLAP only at certain stages in the cell
cycle (Fishman & Singer, 1975).
Levels of PLAP detected in ovarian tumour
tissue extracts by H317 in EIA were variable,
ranging up to 53Ukg-1 wet weight tissue, and did
not correlate with circulating PLAP levels. This
discrepancy between tumour tissue and circulating
PLAP levels has been reported previously in
ovarian carcinoma (Benham et al., 1978). PLAP
has also been detected in various normal tissue
extracts (Goldstein et al., 1982; Millan et al., 1982),
including non-malignant ovarian tissues
(McLaughlin et al., 1984a). Since PLAP is not
detected in the sera of healthy individuals using the
EIA based on H317 (McLaughlin et al., 1983,
1984b), this suggests that the cellular release of
PLAP may determine its subsequent detection in
circulation more than the tumour load or rate of
PLAP production; cell membrane damage or cell
death may be required before significant PLAP is
released to the circulation. This is relevant to the
finding of circulating PLAP in benign ovarian
disease and also in cigarette smokers (Maslow et
al., 1983; Tonik et al., 1983; McLaughlin et al.,
1984b). In these cases, serum PLAP may result
from damage to organs and subsequent release of
endogenous PLAP.
In conclusion, PLAP has been detected in the
serum and tissue of a significant proportion of
patients with ovarian tumours using sensitive and
specific assays based on a mAb, H317. Detection of
circulating PLAP in this serological assay is a
marker of the presence of an ovarian tumour in
over 30% of women presenting with an abdominal
mass. Furthermore, this H317-based EIA does not
detect the non-tumour, smoking-associated form(s)
of PLAP found in some healthy individuals. In
addition, our results have indicated the usefulness
of H317 for the tissue localization of PLAP-
producing tumour cells.
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